213 related articles for article (PubMed ID: 18930407)
21. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
[TBL] [Abstract][Full Text] [Related]
22. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
23. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
Shami PJ; Maciag AE; Eddington JK; Udupi V; Kosak KM; Saavedra JE; Keefer LK
Leuk Res; 2009 Nov; 33(11):1525-9. PubMed ID: 19193435
[TBL] [Abstract][Full Text] [Related]
24. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
Kumar V; Hong SY; Maciag AE; Saavedra JE; Adamson DH; Prud'homme RK; Keefer LK; Chakrapani H
Mol Pharm; 2010 Feb; 7(1):291-8. PubMed ID: 20000791
[TBL] [Abstract][Full Text] [Related]
25. Nitroreductase-activated nitric oxide (NO) prodrugs.
Sharma K; Sengupta K; Chakrapani H
Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
[TBL] [Abstract][Full Text] [Related]
26. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
27. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
[TBL] [Abstract][Full Text] [Related]
28. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
29. Permeability changes in response to NONOate and NONOate prodrug derived nitric oxide in a blood-brain barrier model formed by primary porcine endothelial cells.
Winter S; Konter J; Scheler S; Lehmann J; Fahr A
Nitric Oxide; 2008 May; 18(3):229-39. PubMed ID: 18284923
[TBL] [Abstract][Full Text] [Related]
30. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
31. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
32. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.
Abdellatif KR; Chowdhury MA; Dong Y; Das D; Yu G; Velázquez C; Suresh MR; Knaus EE
Bioorg Med Chem; 2009 Jul; 17(14):5182-8. PubMed ID: 19500994
[TBL] [Abstract][Full Text] [Related]
33. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
Kiziltepe T; Anderson KC; Kutok JL; Jia L; Boucher KM; Saavedra JE; Keefer LK; Shami PJ
J Pharm Pharmacol; 2010 Jan; 62(1):145-51. PubMed ID: 20723011
[TBL] [Abstract][Full Text] [Related]
34. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.
McMurtry V; Saavedra JE; Nieves-Alicea R; Simeone AM; Keefer LK; Tari AM
Int J Oncol; 2011 Apr; 38(4):963-71. PubMed ID: 21271218
[TBL] [Abstract][Full Text] [Related]
35. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells.
Qiu M; Chen L; Tan G; Ke L; Zhang S; Chen H; Liu J
Sci Rep; 2015 Oct; 5():15104. PubMed ID: 26458509
[TBL] [Abstract][Full Text] [Related]
36. Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.
Chakrapani H; Maciag AE; Citro ML; Keefer LK; Saavedra JE
Org Lett; 2008 Nov; 10(22):5155-8. PubMed ID: 18956868
[TBL] [Abstract][Full Text] [Related]
37. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
Heckler M; Osterberg N; Guenzle J; Thiede-Stan NK; Reichardt W; Weidensteiner C; Saavedra JE; Weyerbrock A
Tumour Biol; 2017 Jun; 39(6):1010428317703922. PubMed ID: 28653883
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.
Guenzle J; Garrelfs NWC; Goeldner JM; Weyerbrock A
Mol Neurobiol; 2019 Sep; 56(9):6046-6055. PubMed ID: 30715649
[TBL] [Abstract][Full Text] [Related]
39. Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "Double JS-K".
Holland RJ; Maciag AE; Kumar V; Shi L; Saavedra JE; Prud'homme RK; Chakrapani H; Keefer LK
Chem Res Toxicol; 2012 Dec; 25(12):2670-7. PubMed ID: 23106594
[TBL] [Abstract][Full Text] [Related]
40. Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez CA; Chen QH; Citro ML; Keefer LK; Knaus EE
J Med Chem; 2008 Mar; 51(6):1954-61. PubMed ID: 18314945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]